(Spectrum Health) A paper published September 27 in Scientific Reports shows the positive results of a phase II clinical trial using the oral medication DFMO to prevent relapse in children with High Risk Neuroblastoma (HRNB).
from EurekAlert! - Social and Behavioral Science https://ift.tt/2P3h2Mb
No comments:
Post a Comment